Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,159 shares of the biotechnology company’s stock after acquiring an additional 354 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Exelixis were worth $1,937,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC raised its stake in shares of Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock worth $52,884,000 after buying an additional 704,786 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Exelixis during the 3rd quarter worth approximately $14,979,000. Burney Co. purchased a new position in shares of Exelixis during the 4th quarter worth approximately $12,267,000. Finally, Robeco Institutional Asset Management B.V. raised its stake in shares of Exelixis by 263.1% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 483,064 shares of the biotechnology company’s stock worth $12,536,000 after buying an additional 350,026 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Exelixis

In related news, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction on Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now owns 30,406 shares in the company, valued at approximately $1,060,561.28. This trade represents a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the transaction, the executive vice president now owns 303,310 shares in the company, valued at $11,216,403.80. The trade was a 14.79 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 130,343 shares of company stock worth $4,789,234. 2.85% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Truist Financial increased their target price on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Stifel Nicolaus raised their price objective on Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Wednesday, February 12th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 19th. Brookline Capital Management started coverage on Exelixis in a research note on Monday, December 23rd. They issued a “buy” rating for the company. Finally, Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $30.00 to $40.00 in a research note on Monday, January 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $37.24.

Exelixis Stock Up 2.8 %

EXEL stock opened at $38.69 on Friday. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $38.72. The stock’s fifty day simple moving average is $34.53 and its 200-day simple moving average is $31.62. The stock has a market capitalization of $10.83 billion, a price-to-earnings ratio of 21.86, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.